-
Mashup Score: 0
This new data indicates that while it is not a physically limiting disease, alopecia areata can substantially affect patients’ lives on an individual and national level.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
No statistically significant differences in retention rates were observed among those treated with baricitinib monotherapy or in combination with methotrexate.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
No statistically significant differences in retention rates were observed among those treated with #baricitinib monotherapy or in combination with methotrexate. https://t.co/beAn23M6c9 #RheumatoidArthritis
-
-
Mashup Score: 0Diabetes Dialogue: ADA 2023 Recap - 10 month(s) ago
After a whirlwind conference packed with special episodes and late-breaking data, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss their top takeaways from ADA 2023.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Last week, @DianaMIsaacs and @natalie_bellini hosts of #DiabetesDialogue, sat down to record a recap of their top takeaways from #ADA2023. In this clip, Isaacs discusses data from orforglipron: https://t.co/sjQqijIk3S #Diabetes https://t.co/2cbfLCwAIk
-
-
Mashup Score: 0Q&A: One-Year Efficacy, Safety of Risankizumab in Patients with Psoriatic Arthritis - 10 month(s) ago
In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of #risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs. https://t.co/j0XtDYiSo7 https://t.co/K1FtxoOCqH
-
-
Mashup Score: 0Adverse Events and SSRI Changes According to Online Drug Reviews - 10 month(s) ago
The study provides valuable insights into the medication behavior of patients receiving SSRIs.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
By analyzing patient and caregiver online drug reviews, an investigation shed light on the reasons behind #SSRI medication changes and the importance of patient-reported adverse events. https://t.co/6GYRgYuWWT https://t.co/QaI7PEaStC
-
-
Mashup Score: 0Long COVID Research and Breakthroughs with Julia Moore Vogel, PhD, MBA - 10 month(s) ago
In the latest Lungcast, a nationally-leading researcher and long COVID patient discusses what’s known and unknown about the chronic viral syndrome.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
New #Lungcast! Dr. Rizzo of the @LungAssociation discusses everything #LongCovid with leading researcher and patient @julialmv. Listen to or watch the new episode here: https://t.co/44XlPr08bt
-
-
Mashup Score: 0Jemima Mellerio, MD: New Treatments for Epidermolysis Bullosa - 10 month(s) ago
In this interview segment, Dr. Mellerio spoke about the contents of her presentation titled ‘New Treatment Approaches for Epidermolysis Bullosa.’
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
In this interview, Dr. Mellerio from @GSTTnhs spoke about the contents of her presentation on new treatment approaches for epidermolysis bullosa. #ButterflyDisease View the new interview clip here: https://t.co/WlOYx3nOKJ
-
-
Mashup Score: 030-Month Data from ATTRibute-CM Support Acoramidis Use in ATTR-CM - 10 month(s) ago
Announced on July 17, 30-month data from the ATTRibute-CM trial provide the most comprehensive insight yet into the long-term effects of acoramidis use in patients with transthyretin amyloid cardiomyopathy.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Earlier today, @BridgeBioPharma announced positive 30-month data from part B of the ATTRibute-CM trial. Learn more about results from the phase 3 trial, which will be used in an NDA submission expected by the end of 2023: https://t.co/7gpchWyjRB #Cardiotwitter #Cardiomyopathy
-
-
Mashup Score: 0
“These findings may be used to change attitudes toward mental health disorders, promote greater mental health literacy, and promote policies to support needed services,” investigators write.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
The high lifetime incidence of mental health disorders, coupled with the observed socioeconomic difficulties, calls for a shift in societal attitudes and increased mental health literacy. https://t.co/s9JzyxP6gt
-
-
Mashup Score: 0Revolutionizing Rheumatology: Exploring the Impact of Telemedicine in Transforming Care - 10 month(s) ago
Although the benefits of telehealth are clear, it is not without its challenges. As the field of rheumatology moves into a post-pandemic world, the future of telemedicine hangs in the balance.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Although the benefits of #telehealth are clear, it is not without its challenges. As the field of #rheumatology moves into a post-pandemic world, the future of telemedicine hangs in the balance. Learn more: https://t.co/8zG4ypoNEC
-
ICYMI: This new data indicates that while not a physically limiting disease, #AlopeciaAreata can substantially affect patients’ personal/professional lives on an individual & national level: https://t.co/mtaVXLtRDT